The study of exablate blood-brain barrier disruption for Alzheimer's disease

Ali Rezai is starting a new clinical trial of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Aduhelm Therapy.

The purpose of this study is to assess the safety and feasibility of administering standard of care monthly Aduhelm (Aducanumab) infusion therapy in combination with opening the blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).

The clinical trial started in July 2022 and will continue throughout July 2029.

Treatment intervention related serious adverse events will be primary outcome measure. The total number of serious adverse events following each treatment through end of the study.

For more details: https://ichgcp.net/clinical-trials-registry/NCT05469009.